Results 101 to 110 of about 42,597 (192)
What's New? Investigating the spectrum of (likely) pathogenic germline variants (LP/PVs) in hereditary breast and ovarian cancer (HBOC) genes in pediatric malignancies by unselected genotyping identified 44% (12/27) of clinically unsuspected cases. Burden testing demonstrated considerable associations between monoallelic LP/PVs in five HBOC genes and ...
Katharina Daugs +11 more
wiley +1 more source
Xiaoying Xu,1 Qiongli Zhai,1 Hao Jin,2 Yong Yu,3 Dongmei Han,2 Huilai Zhang,4 Kai Fu,5 Bin Meng1 1Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer ...
Xu X +7 more
doaj
Background: Acute lymphoblastic leukemia (ALL) is a malignancy with aggressive tumors of immature lymphocytes. T-cell immunoglobulin and mucin-domain 3 (TIM-3) is a Type I transmembrane glycoprotein which is involved in cell proliferation.
Narges Zargar Balajam +4 more
doaj +1 more source
ABSTRACT Background Gamma‐glutamyltransferase (GGT) is a membrane‐bound enzyme involved in glutathione metabolism and oxidative stress regulation. Although it is traditionally viewed as a liver function marker, emerging evidence suggests that its aberrant expression is closely associated with tumorigenesis, progression, and therapeutic resistance ...
Fei Wang +11 more
wiley +1 more source
Molecular mechanisms in haematological malignancies [PDF]
Haematopoiesis requires the constant production of large numbers of peripheral blood cells. This process is under tight control of transcription factor networks as well as cytokines, growth factors and hormones.
Avellino, Roberto +2 more
core
Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. [PDF]
TCF3-HLF-positive acute lymphoblastic leukemia (ALL) is currently incurable. Using an integrated approach, we uncovered distinct mutation, gene expression and drug response profiles in TCF3-HLF-positive and treatment-responsive TCF3-PBX1-positive ALL. We
Amstislavskiy, V. +66 more
core +1 more source
Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia [PDF]
Several chemo-resistance mechanisms including the Bcl-2 protein family overexpression and constitutive activation of the PI3K/Akt/mTOR signaling have been documented in acute lymphoblastic leukemia (ALL), encouraging targeted approaches to circumvent ...
ALLEGRETTI, MATTEO +12 more
core +1 more source
High expression of ID family and IGJ genes signature as predictor of low induction treatment response and worst survival in adult Hispanic patients with B-acute lymphoblastic leukemia [PDF]
Table S4. Complete list of signaling pathways dysregulated in patients who achieved complete remission therapy. Signaling pathway analysis was done using MetaCore KPA using the set of 442 genes differentially expressed between good and poor response ...
Alba L. Combita +13 more
core +6 more sources
Background Although blinatumomab, a bispecific T cell engaging antibody, exhibits high clinical response rates in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (B-ALL) and B cell non-Hodgkin’s lymphoma (B-NHL), it still ...
Xiaolong Zhang +9 more
doaj +1 more source
Dysregulated RasGRP1 Responds to Cytokine Receptor Input in T Cell Leukemogenesis [PDF]
Enhanced signaling by the small guanosine triphosphatase Ras is common in T cell acute lymphoblastic leukemia/lymphoma (T-ALL), but the underlying mechanisms are unclear. We identified the guanine nucleotide exchange factor RasGRP1 (Rasgrp1 in mice) as a
Ammon, Kristin +17 more
core +1 more source

